Watch our webinar with Alterity Therapeutics, featuring Managing Director, CEO Dr David Stamler. A presentation followed by live Q&A with the audience.

Alterity Therapeutics (ASX: ATH | NASDAQ: ATHE) is a clinical-stage biotech developing ATH434, a potential first-in-class oral therapy for Multiple System Atrophy (MSA) - a fatal, rapidly progressing neurodegenerative disease with no approved disease modifying treatments. Phase 2 data showed statistically significant slowing of disease progression, and the FDA has confirmed the registrational pathway for ATH434, with a single pivotal Phase 3 trial on track to initiate by year-end 2026.
Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.